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ABSTRACT
The purpose of this integrative review was to identify, critique, and synthesize the maternal and
neonatal evidence on the prenatal use of probiotics and prebiotics to inform perinatal health
professionals. A comprehensive literature search resulted in 37 studies of prenatal probiotics and 1 on
antepartal prebiotics published from 1990 through 2011 that reported maternal, fetal, and/or neonatal

outcomes. The methodologic quality of the studies reviewed was high, although investigators used
different probiotic combinations and inconsistently reported perinatal clinical outcomes. The
extraction of perinatal outcome variables resulted in identification of 9 maternal and 5 neonatal
categories. Prenatal probiotics significantly reduced the incidence of bacterial vaginosis, increased
colonization with vaginal Lactobacillus and intestinal Lactobacillus rhamnosus, altered immune markers
in serum and breast milk, improved maternal glucose metabolism, and reduced the incidence of
gestational diabetes and preeclampsia. Antepartally, probiotics were associated with significantly
higher counts of Bifidobacterium and Lactococcus lactis (healthy intestinal flora) in neonatal stool.
Prenatal prebiotics significantly increased maternal intestinal Bifidobacterium. No adverse events were
reported and there was evidence of safety and tolerance of prenatal probiotics and prebiotics in the
scientific investigations reviewed. It is recommended that in future investigations of prenatal
probiotics researchers explicitly report maternal and neonatal outcomes.
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Complementary and integrative therapies (CIT) have received a great deal of attention from
consumers.1 Probiotics and prebiotics are considered food2 and are readily available over the counter
to women and families as CITs. A variety of readily available fermented milk products contain live
active probiotic bacteria in varying amounts. While numerous commercially available prenatal vitamins
now contain prebiotics and probiotics, the scientific evidence supporting these formulations is lacking.
Furthermore, some providers are recommending prenatal probiotic supplementation to their clients to
reduce Group B Streptococcus colonization,3 although no clinical trials to date support this practice. In
addition, numerous infant formulas now contain probiotics and prebiotics, but evidence to support
incorporating them is lacking as well.4 Perinatal nurses and providers need detailed information about
the implications of probiotics and/or prebiotics for the woman and neonate so that accurate histories
are obtained and providers can offer the best information to women and families who are considering
prenatal dietary supplements.1
While the scientific information on this topic is available in international journals, it is essentially
absent from the perinatal nursing literature. However, it is well documented that prenatal probiotics
reduce the incidence and severity of allergic disease in children of mothers who consumed these
products.5 While the pediatric benefits of prenatal probiotics are important, a gap remains in the
knowledge about the maternal and neonatal effects and whether these products really impact clinical
outcomes.

BACKGROUND
Probiotics are live microorganisms which, when administered in adequate amounts, confer a health
benefit on the host.2 Most commonly available probiotic supplements contain Lactobacillus and/or
Bifidobacterium, which are part of the normal human microbiome.6 Probiotics enhance the healthy
microbiota of the gastrointestinal and genitourinary tracts in a number of ways.7,8 They produce lactic,
acetic, and other acids that lower the pH in these environments, thus impeding the growth of bacterial
pathogens on mucosal surfaces like the intestines and vagina.8 Probiotics also appear to stimulate the
production of numerous substances that work together to improve healthy microflora and displace

harmful bacteria.8 These substances include vitamins, bacteriocins, enzymes, and biosurfactants that
alter the surface tension and reduce pathogen adherence to the mucosa.8–10 Probiotics are thought to
work synergistically with the host immune system to stimulate specific lymphocytes, cytokines, and IgG
and IgA antibodies to fight infection.8
Prebiotics are not live organisms11 but are fermented food ingredients that can be used by bacteria to
confer health benefits upon the host.12 Prebiotics serve as food for species of Lactobacillus and/or
Bifidobacterium, encouraging growth of these beneficial bacteria which in turn may inhibit the growth
of pathogenic bacteria where they have colonized.8

PURPOSE
An integrative review was chosen as the most robust approach to allow the inclusion of the diverse
methods used in the body of scientific literature.13 The purpose of this integrative review was to
identify, critique, and synthesize the perinatal evidence on prenatal probiotics and prebiotics. Maternal
and neonatal outcomes derived from the literature are comprehensively detailed in this review. The
goal is to review the evidence as it specifically applies to perinatal practice.13

METHODS
Medical Literature Analysis and Retrieval System (MEDLINE), Cumulative Index to Nursing and Allied
Health Literature (CINAHL), and the Cochrane Library databases were searched using the terms:
probiotics, prebiotics, pregnancy, and women’s health, for articles published from 1990 through
December 2011. Additional hand searches were conducted using reference lists of articles. This process
yielded 251 articles that were screened to identify scientific investigations of prenatal probiotics or
prebiotics that reported maternal and/or neonatal outcomes. The resulting 38 studies that met
criteria, published between 1993 and 2011, were reviewed.
Data were extracted from each article in a systematic manner, using an adaptation of a previously
published instrument.14 During the data evaluation stage, each study was assessed for quality using the
Oxford definitions for levels of evidence.15 The level of evidence ratings for the 36 individual studies
are presented in Table 1. Further during the data evaluation process, it was observed that many of the
studies could be clustered into research collectives on the basis of specific cross-references, common
trial registration numbers, countries in which the research was done, co-authorships, and/or use of the
exact same sample. These observations raised concerns about overrepresenting primary data
sources.13 Table 1 is organized by study design, according to identified research collectives (lettered AH), when applicable. The linkages between studies were not always clear; therefore, the authors
indicated in Table 1 which studies made explicit versus vague connections to the parent study. Prenatal
probiotic interventions were used in a total of 31 randomized placebo controlled trials,16–46 while
prebiotics were explored in only one.47 The remaining 4 investigations of probiotics included 1 quasiexperiment,48 2 prospective cohort studies,49,50 and 1 observational study.51
Two systematic reviews/meta-analyses on prenatal probiotics were included in this integrative review;
both were assessed as level 1 evidence. The studies that appeared in the systematic reviews/metaanalyses and that were analyzed in this integrative review are indicated by symbols in Table 1. Dugoua
et al52 included 8 randomized controlled trials (RCTs) of prenatal probiotics and focused on the safety

of Lactobacillus and Bifidobacterium species related to 3 specific outcomes: cesarean section, birth
weight, and gestational age. Naaktgeboren53 analyzed 25 RCTs for the outcomes of perinatal probiotics
on intestinal microflora, immunity, and maternal and infant nutrient utilization. Then the researcher
conducted meta-analyses using 10 of the RCTs focusing on 3 specific pediatric outcomes: (1) atopic
dermatitis, (2) skin prick testing, and (3) allergic sensitization. However, neither article incorporated
the full range of RCTs, the quasi-experiment, the prospective cohort studies, and the observational
investigation included in this integrative review. In addition, neither article fully addressed the
maternal and neonatal outcomes.52,53

Table 1. Summary of studies of prenatal probiotics and prebiotics
Research collective
letter
Randomized
controlled trials
A
Ab
Ab
Ac
Ab
Ab
Bc
B
Bb
Bc
C
Cb
Cb
Cb
Cb
Cb
Cb
Cb
Db
D
Eb
Eb
Fc
Fb
G
Gb

Author reference
number and year

Country

Sample
size

Trimester when
intervention initiated

Blinding Placebo
controlled

Level of
evidencea

Kalliomaki16 2001d
Rautava17 2000d,e
Rinne18 2005
Gueimonde19 2007d
Kalliomaki20 2008e
Luoto, Kalliomaki21 2010
Kukkonen22 2006d
Kukkonen23 2007d,e
Kukkonen24 2008
Kuitunen25 2009e
Piirainen26 2006
Kaplas27 2007d
Huurre28 2008e
Aaltonen29 2008
Laitinen30 2009
Luoto, Laitinen31 2010
Aaltonen32 2011
Ilmonen33 2011
Kopp34 2007
Kopp35 2008e
Boyle36 2008
Lahtinen37 2009
Prescott38 2008
Wickens39 2008e
Abrahamsson40 2007d,e
Bottcher41 2008e
Nishijima42 2005d
Niers43 2009e
Dotterud44 2010

Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Germany
Germany
Australia
Australia
New Zealand
New Zealand
Sweden
Sweden
Japan
Netherlands
Norway

159
159
96
53
49
113
87
1223
1223
891
140
30
171
256
256
256
256
256
105
105
73
122
105
474
232
109
24
156
415

3
3
3
3
3
3
3
3
3
3
1
1
1
1
1
1
1
1
3
3
3
3
3
3
3
3
N/A
3
3

DB
DB
DB
N/A
DB
DB
DB
DB
DB
DB
DB
DB-SB
DB
DB-SB
DB-SB
DB-SB
DB-SB
DB-SB
DB
DB
DB
DB
DB
DB
DB
DB
N/A
DB
DB

1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
1b
3b
1b
1b

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Allen45 2011

454

3

DB

Yes

1b

Asemi46 2011
Shadid47 2007

United
Kingdom
Iran
Germany

70
48

3
2

SB
DB

Yes
Yes

1b
4

Neri48 1993

Israel

84

N/A

N/A

Yes

3b

Brantsaeter49 2011
Myhre50 2011

Norway
Norway

33 399
18 888

1
1

N/A
N/A

N/A
N/A

2b
2b

N/A

N/A

3b

Quasi experiment
Prospective cohort
studies
Hb
Hb
Observational study

Schultz51 2004
Germany
9
3
Abbreviations: DB, double blind; N/A, not available; SB, single blinded control group.
a
Oxford Center for Evidence-based Medicine Levels of Evidence.15
b
Explicit reference to parent study.
c
Vague reference to parent study.
d
Included in Dugoua et al52 systematic review & meta-analyses.
e
Included in Naaktgeboren53 meta-analyses.

RESULTS
In this section, an overview of the studies reviewed is provided and participant demographics across
the studies are summarized. Probiotic routes, strains, and dosing are explained. Outcome
categorization is introduced, and the maternal and neonatal outcomes are described in detail.

Overview of studies reviewed
Data from studies conducted in 11 countries in which women were given probiotics during pregnancy
were synthesized. A representative sample size was estimated from the 7 research collectives that
conducted RCTs; together these totaled nearly 2000 pregnant women who were likely exposed to
probiotics. Moreover, 2 prospective cohort studies (research collective H) included more than 33 000
women with varying amounts of ingested probiotics in their diets.49,50 Twenty-four pregnant women
were exposed to prebiotics in 1 study reviewed.47

Demographic characteristics of prenatal participants
Participant characteristics were underreported in the articles reviewed. Investigators in 4 studies
performed in Scandinavia and Northern Europe reported the sample race as Caucasian.30–32,35 While
researchers from New Zealand provided details of their diverse sample,39 those from Japan and Iran
did not report the race(s) of their study subjects.42,46 Of the investigations that included the percent of
participants who were college educated,25,26,29–33,45 the median percent who attended college was
70.6% for the probiotic and prebiotic groups and 68.1% for controls. Among those who reported mean
ages,25–27,29–36,38,41,43–48 the results were 30.4 years for probiotic and prebiotic group study subjects and
31.3 years for women in the control groups. Overall, from the partial information available, the
participants appeared to include mature, highly educated adults from primarily homogeneous groups.
Although all the studies reviewed included healthy pregnant women, investigators in 19 had selected
samples of women specifically with a risk of atopy (a predisposition toward developing allergic
hypersensitivity reactions)54 to examine whether prenatal probiotics or prebiotics would reduce
subsequent development of allergic disease in offspring.16,17,21–25,28,35–41,43–45,47 This risk was defined by
the researchers as having at least 1 first degree relative with atopic dermatitis or eczema, allergic
rhinitis, and/or asthma. The purposeful sampling of women with atopic risk suggests that the
outcomes of prenatal probiotics and prebiotics could be different in women without this risk.
Furthermore, studies that preferentially included women with atopic risk also tended to measure longterm pediatric outcomes, beyond the neonatal period, and thus exceeded the time parameter
established for this integrative review.

Routes, strains, and doses of study interventions
Because probiotics are live cultured microbial food supplements,55 the dose is measured by colony
forming units (CFUs) per milliliter, calculated by dividing the number of colonies, multiplied by the
dilution on a Petri dish, by the volume of the culture on the same plate.56 In the 35 individual probiotic
studies reviewed, doses ranged from 1 × 107 to 2 × 1010 CFUs (see Table 2). Most of the probiotic
studies used 1 or more strains of Lactobacillus, and several added at least 1 Bifidobacterium. These
products are available over the counter.

In 27 of the studies, probiotics were administered as capsules and 2 others used oil dilutions.40,41 In the
remaining 6 studies, shown in Table 3, probiotic interventions were in the form of milk or yogurt
products. In addition, one researcher studied a water-soluble prebiotic supplement containing both
galacto-oligosaccharides and long-chain fructo-oligosaccharides derived from cow’s milk.47
Investigators did not provide rationale to explain their choices of probiotic or prebiotic in any of the
studies reviewed. Most of the investigators began the intervention during the third trimester and
continued at least until birth. Six reports were unclear concerning treatment duration,26,27,42,48–50 and a
seventh study only gave probiotics between 28 and 37 weeks’ gestation.46

Table 2. Probiotic species and doses in studies reviewed
Lactobacillus (CFUs)
L. rhamnosus (2.0 × 109 −
2.0 × 1010 )
L. reuteri (1.0 × 108 )
L. rhamnosus (6.0 × 109 )
L. rhamnosus (1.0 × 109 −
1.0 × 1010 )
L. rhamnosus (1.0 × 1010)

Bifidobacterium (CFUs)

L. salivarius (6.25 × 109 )
L. paracasei (1.25 × 109 )
[No Lactobacillus]

B. animalis (1.25 × 109 )
B. bifidum (1.25 × 109 )
B. animalis (1 × 109 )
B. bifidum (1 × 109 )

Other species (CFUs)

B. animalis (9.0 × 109 )
B. animalis subsp lactis (1.0 × 10 −
1.0 × 1010 )
B. breve (2.0 × 108 bid)

Propionibacterium freudenreichii subsp
shermanii (2.0 × 109 bid)

Reference numbers
16, 17, 18, 19, 20, 21, 34,
35, 36, 37, 51
40, 41
38, 39
26, 27, 28, 29, 30, 31, 32,
33
22, 23, 24, 25
45

Lactococcus lactis (1 × 109 )

43

Abbreviations: B, Bifidobacterium; bid, twice daily; CFUs, colony forming units; L, Lactobacillus; subsp, subspecies.
Table 3. Yogurts and fermented milk probiotic products studied
Country Brand
name
Israel
N/A
Japan
Nestlé
Norway

Norway

Iran

Product

Route

Dose

Yogurt
Vaginal 10-15 mL
Fermented Oral
120 g per day
Milk
Biola
Milk
Oral
No-zero
low = 13 mL per day
high = 85 mL per day
Cultura Milk
Oral
No-zero
low = 13 mL per day
high = 85 mL per day
N/A
Yogurt
Oral
200 g per day

pH

Lactobacillus (CFUs)

Bifidobacterium
(CFUs)

Reference
numbers
48
42

<4.5
N/A

L. acidophilus (> 1 × 108 /mL)
L. johnsonii (1.0 × 109 /mL)

N/A

L. acidophilus (1.0 × 108 )/mL
L. rhamnosus (1.0 × 108 )/mL

B. lactis
(5.0 × 109 )

44, 49, 50

N/A

L. acidophilus (1 × 108 )/mL

B. lactis (5.0 ×
109 )

49, 50

4.34.5

L. acidophilus (1.0 × 107 )/ 200g

B. animalis
(1.0 × 107 )

46

Abbreviations: B, Bifidobacterium; CFUs, colony forming units; L, Lactobacillus; N/A, not available; subsp, subspecies.

Categorizing outcomes
All discrete outcomes reported in the scientific investigations were extracted. First, the outcomes were
broadly classified as maternal or neonatal. During the data reduction process for this integrative
review,13 the first 2 authors conducted a content analysis to identify each discrete perinatal study
outcome. Commonalities between studies were identified and combined into categories. These logical
categories provided meaningful descriptions of the major maternal and neonatal outcomes. The third
author confirmed that the categories accurately reflected the data. This inclusive and comprehensive
process resulted in a total of 14 categories. The 9 maternal outcome categories identified were mode
of birth, vaginal flora composition preterm labor, blood pressures and preeclampsia prevention,
glucose metabolism, body mass index (BMI) and weight gain, gastrointestinal outcomes, breast milk
composition, and maternal immunomarkers. The neonatal findings are detailed in 5 categories:
gestational age at birth, fetal cord blood, Apgar scores, anthropometric measures, and gastrointestinal
outcomes. All findings were reported according to these 14 outcome categories and are identified
according to article reference numbers in Table 4.
In the following sections, the statistically significant and clinically relevant perinatal outcomes are
presented according to the categories. Although most maternal and neonatal outcomes were
statistically nonsignificant, a comprehensive presentation is provided in adherence to the principles of
the integrative review process.13 Furthermore, some nonsignificant findings have clinical relevance for
perinatal health professionals as the findings may suggest the safety of the intervention and facilitate
complete disclosure of information by providers to women and their families.

Maternal outcomes
In the following sections, the 9 statistically significant and clinically relevant maternal outcomes are
described. For ease of reference, all the outcome categories are summarized in Table 4. This includes
those studies with nonsignificant findings.
Mode of birth
In most of the 20 investigations that reported cesarean rates in the study and control groups, betweengroup differences were not statistically analyzed. However, according to one meta-analysis,52 there
was no significant difference in mode of birth in the probiotic groups when compared with controls
(OR = 0.88; 95% CI: 0.65-1.19; P = 4). Therefore, based on current limited evidence prenatal probiotics
do not appear to impact the mode of birth.
Vaginal flora and pH
One of the mechanisms of action of probiotics is the acidification of mucosal surfaces like the vagina,
thus inhibiting the growth of pathogens. Vaginal flora or pH were explored in only 3 studies; 2 of which
reported statistically significant findings. Neri et al48 conducted a 3-group comparison of an
intravaginal yogurt intervention for treating bacterial vaginosis, compared to vaginal acetic acid
(tampon soaked in 10-15 mL of 5% acetic acid), and a nontreatment control group. All 32 women in the
yogurt group reported symptom relief after 2 days of treatment. At both 1 and 2 months
posttreatment, women in the yogurt group had a significantly higher bacterial vaginosis cure rate than
those in the acetic acid (P = .04) and the control (P < .0005) groups. Nishijima et al42 studied the impact
of probiotics on the vaginal flora of pregnant women and found that probiotic treatment (n = 32)

significantly increased vaginal Lactobacillus colonization (P = .025) and eliminated pathogenic bacteria
(Gardnerella and Corynebacterium) (no P value provided). Overall, the results suggest that probiotics
reduced the symptoms and presence of bacterial vaginosis and other pathogens within 1 month of
administration. Vaginal flora findings beyond the presence of bacterial vaginosis were not explored in
any of the investigations reviewed.
Table 4. Summary of findings according to outcome category and reference numbers a of studies
Reviewed
Outcome Category

Any significant
findings

Maternal outcomes
Mode of birth (cesarean sections rates) N/A

Exclusively nonsignificant findings

Vaginal flora and pH
Preterm labor
Blood pressures and preeclampsia
prevention
Glucose metabolism
Body mass index and weight gain
Gastrointestinal measures
Breast milk composition
Maternal immunomarkers
Neonatal Outcomes
Gestational age at birth

42, 48
42 and 48b, 50
49

17, 19, 20, 21, 22, 23, 24, 25, 30, 31, 34,
35, 36, 37, 38, 39, 40, 43, 47, 52
47
N/A
26, 29

30, 31, 32
49, 50
37, 47
17, 38, 41
36, 46

N/A
26, 27, 29, 30, 32, 33, 46
19, 30, 51
18, 28, 37
N/A

N/A

Fetal cord blood and pH
Apgar scores (5 and/or 10 min)
Anthropometric measures (birth
weight, length, and/or head
circumference)
Fecal microflora samples

38
N/A
28

16, 17, 18, 20, 21, 23, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 38, 41, 43, 44, 47, 52
16, 17, 27, 34, 36, 44, 47
22, 29, 30, 31, 32
16, 17, 20, 21, 22, 23, 24, 25, 26, 27, 29,
30, 31, 32, 33, 34, 35, 38, 39, 40, 43, 44,
47, 52
23, 47, 51

19, 43

Abbreviation: N/A, not available.
a
Each number represents a study reviewed and its location in the reference list.
b
The data from these 2 studies reviewed were pooled by Othman et al57 in a Cochrane review to determine
statistical significance.

Preterm labor
Because there is an association between bacterial vaginosis and preterm labor, probiotics have a
potential role in prevention.57 In a Cochrane review of prenatal probiotics to prevent preterm labor,57
the results of Nishijima et al42 and Neri et al48 were pooled and it was found that probiotics reduced
the risk of genital infection (particularly bacterial vaginosis) by 81% (OR: 0.19; 95% CI: 0.08-0.48, P =
not reported). However, the authors concluded that there was not enough evidence to determine if
probiotics reduced the incidence of preterm labor.

More recently, Myhre et al50 evaluated the intake of probiotics and the risk of preterm labor in a large
prospective cohort study. In addition to completing other questionnaires, women were asked to
specify the quantity of probiotic milk products consumed (Table 3). Using logistic regression, the
researchers found that women who reported a high intake of probiotic containing foods had a
significantly lower risk of preterm labor (OR = 0.82; 95% CI: 0.681-0.986; P = .035). This study was
limited by the use of recall questionnaires and a lack of clarity in reporting outcomes, but the authors
concluded that probiotics may function by lowering the number of colonies of pathogenic bacteria and
improving vaginal health, thereby limiting systemic inflammation that may play a role in the cascade of
events that lead to preterm labor.57 Current data are insufficient to determine whether or not
probiotics have a role in the prevention of preterm labor.
Blood pressures and preeclampsia prevention
The development and severity of preeclampsia appears to be related to both the maternal immune
system and infections.58 Prenatal probiotics may reduce the placental and systemic inflammatory
processes in ways that modify the maternal immune system to prevent preeclampsia.49 Maternal
blood pressure was measured in 3 studies, among which 1 reported significant findings. Brantsaeter et
al49 explored the relationship between probiotics and the risk of preeclampsia in primiparous women
enrolled in a prospective cohort study. Although this study was limited by the use of dietary recall, the
researchers found that daily probiotic intake significantly reduced the risk of preeclampsia (OR = 0.80;
95% CI: 0.66-0.96; P = not reported). The risk of severe preeclampsia was significantly reduced by
weekly (OR = 0.75; 95% CI: 0.57-0.98; P = not reported) or daily (OR = 0.61; 95% CI: 0.43-0.89; P = not
reported) probiotic intake. These findings suggest that regular probiotics consumption during
pregnancy may play a role in preeclampsia prevention.
Glucose metabolism
In an RCT conducted in Finland healthy pregnant nondiabetic women in the first trimester of pregnancy
(N = 256) were randomized to 1 of 3 groups: (1) dietary counseling and probiotics, (2) dietary
counseling and placebo, and (3) control and placebo. Dietary counseling included intensive instructions
provided by a nutritionist to follow the recommended Nordic prenatal diet32 with special attention to
sources of dietary fat and fiber, but no assessment of the subjects’ preintervention diets were
reported. Laitinen et al30 found that women in the experimental group had a significantly lower mean
plasma glucose level (OR = 0.31; 95% CI: 0.12-0.78; P = .013); the lowest insulin levels (adjusted means
7.55, 7.32, and 7.27 mU/L; P = .032); and, during the last trimester, the highest index of insulin
sensitivity obtained from a fasting sample (adjusted means 0.37, 0.35, and 0.35; P = .028). Luoto et
al31 reported a significantly lower risk of gestational diabetes, 13% in the probiotics/diet group
compared with a combined average of 35% across the placebo groups (P = .003). Aaltonen et al32 also
reported a significantly lower incidence of gestational diabetes, 0% in the probiotics/diet group
compared with a combined average of 10.8% in the placebo groups (P = .033). These studies were all
limited by the use of participants’ dietary recall, yet these findings suggested that dietary counseling
combined with probiotics could be used to both prevent and partially treat glucose disorders of
pregnancy but more prospective study is needed.

Body mass index and weight gain
Because probiotics are considered food, the inclusion of weight gain as an outcome seems logical.
While seven RCTs included body mass index (BMI) and/or pregnancy weight gain as study variables,
only 2 prospective cohort studies from a single research collective reported statistically significant
findings.49,50 Myhre et al50 found that women who consumed high levels of probiotic containing foods
also had significantly lower prepregnant BMIs (P < .001) than those who consumed lesser amounts.
Brantsaeter et al49 found that for women of normal prepregnant weight, there was no evidence that
probiotics significantly altered overall maternal weight gain. More consistent inclusion of maternal
prenatal and postpartum weight measurements in probiotics and prebiotics research is needed to
guide clinicians.
Gastrointestinal measures
Because probiotics and prebiotics act on the mucosal surface of the gut, rectal swabs and fecal samples
were used to assess changes in maternal intestinal colonization in 3 studies. While Lahtinen et al37
found no difference in Bifidobacterium counts, the probiotic group had a significantly greater
colonization of Lactobacillus rhamnosus (66.7%) than the placebo group (11.8%) (OR = 5.67; 95% CI:
2.19-14.64; P < .001). By detecting the intervention probiotic in the maternal gastrointestinal tract, the
researchers demonstrated that it survived the digestive processes of the upper tract and can benefit
the mucosal surfaces of the colon. In the study by Schultz et al,51 L. rhamnosus was not detectible in
rectal swabs done at 1 month postpartum in 3 of 6 women who took prenatal probiotics. Shadid et al47
demonstrated a significant increase in the proportion of intestinal Bifidobacterium colony counts in
women who took prebiotics compared with women in a placebo group (21% and 12.4%, respectively, P
= .026). Because intestinal colonization with healthy bacteria has implications for both maternal and
neonatal health, a more rigorous assessment of gastrointestinal measures would better inform clinical
practice.
Prenatal progesterone levels lead to a physiologic slowing of the maternal gastrointestinal tract.
Probiotics are often used to improve gastrointestinal symptoms. Laitinen et al30 found pregnant
women in both study groups reported minor gastrointestinal discomforts, such as flatulence, loose
stools, or constipation at study initiation. Specifically 7% of the diet/probiotic, 8% in the diet/placebo,
and 3% in the control/placebo groups reported these symptoms. Subsequently, because of the relative
rarity of the symptoms, the researchers reported a combined prevalence of gastrointestinal symptoms,
which were reduced to 2% in the second trimester and 0.5% in the third. This finding is clinically
significant, because probiotic intake was not associated with any increase in the incidence of minor
gastrointestinal discomforts in pregnant women, Gastrointestinal outcomes were not reported in most
of the scientific investigations reviewed, representing a missed opportunity to attempt to address this
important aspect of symptom management and quality of life during pregnancy. More investigation is
needed to identify the impact of prenatal probiotics on the physiologic changes of pregnancy, such as
constipation.
Breast milk composition
There is a suggestion in the literature that intestinal microflora play a role in breast milk composition.41
Because there is a correlation between intestinal production of Transforming Growth Factor-beta (TGFβ) (a cytokine associated with allergic sensitization) and the newborn’s ability to make Immunoglobulin

A (IgA) antibodies and avoid allergies,17 these components in breast milk were evaluated in 6 studies.
Three of the articles reported significant differences between groups. Rautava et al17 examined breast
milk at 3 months postpartum while the mother was just finishing the probiotic or placebo treatment.
The researchers found that the concentration of TGF-β2 was higher in the breast milk of probiotic
group mothers than in that of controls (P = .018). In Bottcher et al,41 probiotics were administered only
until the time of birth. There was no significant difference in breast milk IgA between groups, although
significantly lower levels of TGF-β2 were identified in the breast milk of women who had the probiotic
intervention (L. reuteri) found in their feces, compared with controls (P = .04). Probiotic treated
women also had higher Interleukin 10 (IL-10) (an anti-inflammatory cytokine) in colostrum than
controls (P = .046). However, neither difference was sustained in breast milk samples taken at 1 month
postpartum. While the TGF-β2 findings of Bottcher et al41 contradicted those of Rautava et al,17 both
described their results as protective against atopic disease development.
In a 3-group RCT, Prescott et al38 studied women ingesting 2 different probiotics compared with a
placebo and measured breast milk immune markers. The breastfeeding women continued the
probiotic or placebo through 6 months postpartum. Prenatal Bifidobacterium lactis ingestion resulted
in significantly higher TGF-β1 levels in early (1 week) breast milk (P = .028). At 1 week, women in both
probiotic groups also had significantly higher levels of IgA in breast milk (B. lactis, P = .008; L.
rhamnosus, P = .011). At 3 months, only women in the B. lactis group had significantly higher levels of
breast milk IgA (P = .027). It appears that probiotic supplementation during breastfeeding may result in
at least some important immunologic benefits for the neonate, but to sustain these changes,
continued probiotic ingestion may be needed. Because most of the studies were conducted in
Northern Europe, where breastfeeding rates are high, it may be a missed opportunity that only a few
studies examined breast milk composition.
Maternal immunomarkers
Significant findings related to maternal immunomarkers following probiotic administration were found
in 2 RCTs. Boyle et al36 found that prenatal administration of L. rhamnosus significantly decreased
human interferon γ (IFN-γ ) (a protein released as part of the immune response to pathogens) (P = .02).
Asemi et al46 found that Lactobacillus acidophilus and Bifidobacterium animalis administration during
pregnancy significantly decreased the serum level of highly sensitive C-reactive protein (a marker for
inflammation) (P = .001). Proinflammatory factors are increased during pregnancy and these factors
are associated with insulin resistance and pregnancy complications such as gestational diabetes,
premature birth, and preeclampsia.46 These factors need to be included as outcomes in future
investigations to better elucidate probiotic mechanisms of action.

Neonatal outcomes
In Table 4, all of the neonatal outcome categories are summarized with relevant references.
Throughout this integrative review, details of statistically significant findings are presented. Although
examination of neonatal outcomes revealed numerous statistically nonsignificant findings, a number of
these outcomes are clinically relevant and therefore important to providers and their clients. It is
possible that the absence of significant differences between groups may underscore the safety of
prenatal probiotic exposure for the offspring.

Gestational age at birth
Variations in the timing of probiotic initiation reported among the studies limited the examination of
the impact of prenatal probiotics on preterm birth prevention. However, gestational age at birth was
included as a neonatal outcome in more than one-half of the studies and no significant differences
were found between probiotic and control groups. In one metaanalysis,52 a nonsignificant increase in
gestational age of 0.4 weeks in the infants of women in the probiotic versus control groups (P = .336)
was found. Current evidence does not suggest an association between antenatal probiotics and
clinically relevant differences in gestational age.
Fetal cord blood and pH
Researchers in 8 of the studies reviewed attempted to examine the prenatal use of probiotics or
prebiotics for reducing the expression of immunoglobulin E antibodies associated with the
development of atopic disease in children. However, as previously described, the long-term measures
extended beyond the neonatal period and the parameters established for this integrative review. Only
Prescott et al38 reported significant between-group differences in cord blood markers of allergic
response. There was significantly less soluble cluster of differentiation 14 (a cell marker of atopic
disease) in B. lactis group neonates (P = .045) and higher levels of interferon-γ cytokine in L. rhamnosus
group neonates (P = .030) compared with the placebo group. The authors concluded that probiotics
may modify cytokines and other parameters that play a role in neonatal immune responses. Only in the
investigation of prebiotics did the researchers47 measured cord pH; no differences were found
between prebiotic and control group neonates. The lack of consistent markers and the inclusion of
women at risk for atopic disease limits the generalizability and utility of these findings.
Apgar scores
Apgar scoring is a universal neonatal measure that indicates the need for immediate newborn
resuscitation.59 Investigators in only 6 of the studies reviewed explored 5- and/or 10-minute Apgar
scores and reported no significant differences. With so little attention given to Apgar scores, there is
insufficient evidence to draw conclusions about this outcome.
Anthropometric measures
Investigators in 24 of the studies reviewed included at least 1 newborn anthropometric measure (birth
weight, length, and/or head circumference), and all but 2 reported no significant differences between
groups. Huurre et al28 reported a significant difference in birth weight and length, with probiotic group
infants averaging 170 g lighter (P < .05) and 0.6 cm shorter (P < .05). The weight difference
(approximately 6 ounces) might be clinically significant for some dyads, while the shorter length (0.2 in)
is unlikely to have an impact. A contradictory finding was reported in a meta-analysis,52 in which there
was a nonsignificant trend toward larger birth weights (45 g increase or 1.6 ounces) in probiotic infants
than in controls (P = .699).
Without consistent information provided about birth weights in the studies reviewed, it is impossible
to determine whether the incidence of low-birth-weight infants is impacted by probiotics or
prebiotics.52 Only limited information on birth weight ranges was reported in one-half of the studies
reviewed. The incidence of low birth weight was not reported by any investigators. Therefore,
information is insufficient to draw conclusions about the impact of prenatal probiotics and prebiotics
on low birth weight, although analysis of this aspect would be important to include in future work.52

Luoto et al31 investigated prenatal and postnatal infant growth using maternal antepartal dietary
modifications and probiotics in women with gestational diabetes. When analyzed by neonatal birth
weight and length, significantly more infants of control group mothers with gestational diabetes were,
on average, both heavier (426 g) and longer (1.7 cm) (P = .001) than probiotic exposed infants. This
difference is also clinically significant as it amounts to nearly a pound lighter for probiotic group infants
of diabetic mothers. Therefore, among women with gestational diabetes, findings suggest a possible
protective effect against macrosomia. Because neonatal anthropometrics often play a role in birth
outcomes, inclusion of these measures in sufficient detail in future interventional studies of prenatal
probiotics and prebiotics would be simple yet meaningful.
Fecal microflora samples
Enhancement of neonatal gut microflora is one goal of prenatal probiotic ingestion. In 5 investigations
reviewed, neonatal fecal samples were tested for the presence of probiotic bacteria. The investigators
were attempting to identify if the probiotic bacteria ingested by the mother prenatally could be
retrieved from neonatal fecal samples. Authors of 2 of the studies found significant between-group
differences in fecal bacteria. Gueimonde et al19 analyzed neonatal fecal samples at 5 days of age and
found significantly more B. breve in probiotic group neonates than in controls (P = .044), while B.
adolescentis was significantly higher in placebo group neonates (P = .043). These differences were not
significant in the 3-week stool samples (P = .069), but the researchers found that the intestinal
microflora of neonates whose mothers took probiotics were more complex and less similar to their
mothers. Niers et al43 examined neonatal stools weekly during the first month of life and found that
colonization with Lactococcus lactis was significantly increased in the feces of probiotic group neonates
at 2 weeks (P < .01), and at 3 to 4 weeks of life (P < .001). However, there were no significant
differences in Bifidobacterium counts between groups in this study. While Bifidobacteium
predominates in a healthy gut, it takes several months to fully develop during infancy.60
Because the bacterial flora of the neonatal gut is markedly affected by mode of birth, environmental
exposures, and feeding methods, interpretation of gastrointestinal outcomes of probiotic and prebiotic
use must be examined within those contexts.61 The presence of Bifidobacterium and overall bacterial
complexity and diversity are important indicators of a healthy neonatal intestinal microbiota.19 These
measures were omitted in most of the studies reviewed; more in depth, long-term study is needed.

Adverse effects of probiotics and prebiotics
No adverse effects attributable to the use of prenatal probiotics or prebiotics were reported by
investigators in any of the studies reviewed. In 1 article, neonatal morbidities such as jaundice,
hypoglycemia, infection, the need for supplemental oxygen administration, and other more rare
complications were not significantly different between probiotic and control group neonates.24 Allen et
al45 focused on adverse events as the primary study outcome tracked using World Health Organization
International Statistical Classification of Disease Criteria and questionnaires completed by mothers and
providers. Adverse events such as infections and diseases of the nervous, respiratory, and digestive
systems were reported by 15 women (6.8%) in the probiotic group compared with 21 (9.0%) in the
placebo group, but these differences were not statistically significant. Overall, no negative sequelae
were attributed to prenatal probiotics or prebiotics.45

In healthy individuals, probiotics are not thought to be systemically absorbed.62 Although probiotic
bacteria such as Lactobacillus are “generally regarded as safe,”2,63 and were included in nearly all of the
study probiotic interventions, some concerns persist. For example, there are theoretical risks of
probiotics for pregnant women and neonates due to their slightly compromised immune responses.53
The development of serious infections in immune-compromised patients exposed to probiotics is
considered possible.53 Prebiotic use would not introduce strains of new bacteria and therefore should
pose no potential risk.53 In summary, no evidence of adverse effects of prenatal probiotics or prebiotics
were documented in this review.

DISCUSSION
More than one-half of the prenatal probiotic studies reviewed were conducted for the purpose of
reducing atopic disease in children. Prenatal probiotics have a well-established record of significantly
reducing the incidence and severity of atopic disease in offspring.5 Unfortunately, many maternal and
neonatal outcomes were largely ignored in the research studies reviewed, highlighting missed
opportunities to build a strong body of perinatal evidence about the intervention.

Summary of statistically significant findings
Overall, few statistically significant maternal and neonatal outcomes associated with prenatal probiotic
use were reported among the studies reviewed. However, the statistically significant maternal
outcomes of prenatal probiotic ingestion are detailed as follows: reduced rates of bacterial
vaginosis,48,57 increased vaginal bacterial colony counts of Lactobacillus,42 increased intestinal
colonization with L. rhamnosus,37 lowered the incidence of preeclampsia,49 lowered the incidence of
gestational diabetes,31,32 improved glucose metabolism,30 altered immune markers in serum,36,46 and
those in breast milk17,38,41 and, when taken in high amounts, according to one prospective cohort50
study and a Cochrane review,57 may reduce the risk preterm labor. Prebiotics significantly increased
maternal Bifidobacterium in the intestines.47
Similarly for the neonate, prenatal probiotics were associated with significantly higher intestinal
colonization with Bifidobacterium19 and Lc. Lactis.43 Prenatal probiotics also modified several cord
blood38 immunomarkers, placental cytokines, and other protective and/or growth promoting factors.27

Limitations
This integrative review has several limitations. First, it was difficult to determine with precision how
the investigators analyzed specific measures and variables. A number of the studies reviewed did not
contain clear reporting of statistics and/or between-group differences on maternal and neonatal
outcomes. Despite careful consideration of the research collectives, some of the perinatal outcomes
may have been overrepresented due to the inclusion of secondary analyses. Furthermore, even when
authors did clearly indicate that they were using a subsample of a larger, earlier study, the number of
women who were exposed to probiotics during pregnancy may be overestimated. The use of atopy as
an eligibility criterion in more than one-half of the studies reviewed threatens the generalizability of
the findings. In addition, the investigators used a variety of probiotics. There is emerging evidence that
the effect of probiotics is strain specific and the findings from the use of one probiotic may not be
attributable to another.8 Finally, given that there was only 1 study of prebiotics, conclusions about
perinatal outcomes of prebiotic administration are limited.

Clinical implications
Most of the probiotic interventions were initiated in the third trimester and included once daily oral
dosing with a probiotic containing Lactobacillus, and several added at least 1 Bifidobacterium. There
was no evidence that taking probiotics beginning in the first trimester would be harmful. On the basis
of the 2 prospective cohort studies, the use of live cultured milk products may be considered as a
nutritional intervention valuable to all pregnant women. For example, the consumption of
approximately 3 ounces of a cultured milk product daily was associated with a significant decrease in
the risk of spontaneous preterm birth.50 The lowest risk of severe preeclampsia was associated with
the consumption of approximately 7 ounces of cultured milk product daily.49 While these specific
products may not be available in the United States, this review and the details provided could be used
to select similar products that could meet the needs of pregnant women. When compared with the
CFU dosing in most of the probiotic capsule supplements in the studies reviewed, substituting cultured
milk products would require the consumption of large amounts to achieve a similar dosage. Because of
the diversity of the studies reviewed, there is no single probiotic supplement that could be
recommended universally to all pregnant women.
Pregnancy is an opportune time for probiotic use because of the potential positive effects for the
health of the woman and her neonate. Probiotics appear to hold promise for clinicians as
nonpharmacologic, readily available, well-tolerated, low-risk therapies for women with minor
complaints and may play a role in preventing major pregnancy complications. However, the maximal
and immediate benefits for pregnant women appear to exist primarily during active probiotic
ingestion, although the immunologic benefits for the infant exposed prenatally may persist for months
or years.21 The outcomes of postpartum ingestion have not been clearly addressed in the scientific
literature because several investigators continued probiotic ingestion for infants and sometimes for
the mother during breastfeeding. On the basis of this review, prenatal probiotic and/or prebiotic use
appears to be low risk and may lead to a variety of potential short- and long-term benefits for healthy
women.
The long-term safety for children born after probiotic use in pregnancy was evaluated by Luoto et al21
at intervals up to 10 years of age. There were no adverse events or perinatal deaths in any women or
infants involved in the study. While 26% of the study children exposed to probiotics during pregnancy
were lost to follow-up and many of the outcomes were beyond the parameters for this review, the
researchers concluded that probiotics did not significantly alter the duration of pregnancy, the mode of
birth, prenatal or postnatal growth, rates of sepsis, Apgar scores, or the duration of breastfeeding.

Research implications
Detailed information about the effect of prenatal probiotics and prebiotics is vital for researchers,
clinicians, and parents. There is emerging evidence that probiotics inhibit pathogens in the human
microbiome.7,8 For example, an in vitro study showed that a probiotic composed of Lactobacillus and
Bifidobacterium inhibited Group B Streptococcus growth64; this finding needs in vivo testing.
Future research with a focus on more clarity and inclusion of consistent maternal and neonatal
outcomes and measures is needed to enhance the clinical utility of the findings. Apgar scoring,
newborn weight ranges (with incidence of preterm birth and low birth weight) could readily be

included. Explicit reporting of sample demographics and outcomes, such as vaginal flora and pH,
intestinal microbiota, immune markers, and the incidence of minor adverse effects would better
contribute to the body of knowledge. The heterogeneity in outcome measures in this body of literature
limits researchers’ abilities to conduct systematic reviews. Furthermore, analysis of between-group
differences would facilitate replication and the conduct of meaningful meta-analyses.
The omission of race as a demographic variable in all but 5 studies may be due to the fact that most
were conducted in countries that have homogeneous populations. Because colonization with
microbiota varies by race/ethnicity65 and geographic location,66 more research that explores the
outcomes of prenatal probiotic use in diverse women from countries with heterogeneous populations
is warranted. In addition, future investigations could be strengthened by including rationale for the
choice of probiotics or prebiotics, the dose chosen, and the mode of administration.
Well-controlled double blind trials of larger populations of healthy women (including those not at risk
of atopic disease) are needed. Important clinical issues urgently need to be addressed, such as preterm
labor prevention and promoting the establishment of healthy neonatal intestinal flora. The latter
investigation requires controlling for mode of birth and type of infant feeding. The interactions
between maternal and neonatal physiology were explored in only 11 studies.17–19,27,28,34,36,38,41,46,47
Most of the research in this integrative review focused on long-term infant and pediatric outcomes.
Critical measures during the transition from pregnancy through the first month of life, such as
comparisons of maternal and neonatal intestinal flora,19 breast milk cytokines,17,18,28,41 other
immunomarkers34,36,38,46,47 and placental fatty acids,27 were largely ignored.

CONCLUSION
In this integrative review, findings are presented on the clinical application of prenatal probiotics
during pregnancy. Evidence was noted for the safety and tolerance of probiotics used during
pregnancy, which is an opportune time to positively affect the long-term health of the developing fetus
and child. Prenatal probiotics are associated with a decrease in atopic disease and may also have
demonstrated impacts on other perinatal outcomes, although inconsistencies in measuring and
reporting the outcomes limited the utility and generalizability of these findings. Only 1 study of
prebiotics was found. Well designed and controlled clinical trials of diverse healthy women using wellcharacterized strains of probiotics with rigorous assessment of the impact on intestinal and vaginal
microbiota are needed to better determine clinically relevant perinatal outcomes.
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